Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape
Semaglutide and tirzepatide represent foundational options in contemporary obesity pharmacotherapy. Semaglutide offers robust cardiovascular protection; tirzepatide yields greater weight loss and broad metabolic benefits. Both agents require clinicians to reconceptualize obesity as a chronic disease needing ongoing pharmacological management.
Authors
- Carel Wynand le Roux (ORCID: https://orcid.org/0000-0001-5521-5445)
- Michael Crotty (ORCID: https://orcid.org/0000-0003-3864-6299)
- Alvin Mondoh
Institutions
- University College Dublin (IE)
- Oregon Weight Loss Surgery (US)
- Sports Surgery Clinic (IE)
Publication Details
- Journal
- Expert Opinion on Pharmacotherapy
- Published
- 2025-11-22
- DOI
- https://doi.org/10.1080/14656566.2025.2601060
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00